Clinical trials: Cancers Expressing HER-2 and/or CEA

Cancers Expressing HER-2 and/or CEA

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

• Completed
• Age: 18 years and older
• Phase 1

To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as intramuscular injections followed by electrostimulation in cancer patients.

Trial name

NCT00250419

Testing

V930

Volunteers

26 people

Sponsor

Merck Sharp & Dohme LLC